

CLINICAL RESEARCH NEWS

CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS PENDING ACTIVATION

Research Base	Title	Description
ALLIANCE	A232301CD: AYA Access Study: An Enhanced eHealth and Chat-Bot Enabled Delivery Model for Clinical Genetic Services in Community AYA Cancer Patients	<ul style="list-style-type: none"> • 465 Adolescents and young adults (AYAs), 18-39 y/o • Protocol under review • Expected activation: Sept. 2025
	A232402CD: PAGODA Randomized Trial of a Proactive Graduated Dose Adjustment Algorithm for FOLFOX Chemotherapy to Prevent Unplanned Delays	<ul style="list-style-type: none"> • GI cancer patients • Protocol under review • Expected activation: Fall 2025
SWOG	<p>S2417CD: Current Together After Cancer (CTAC): A Pragmatic RCT of an Intervention to Improve Use of Colorectal Cancer Follow up Care. Expected activation: August 2025</p> <ul style="list-style-type: none"> • This study will address a key gap in cancer care delivery, specifically that many colorectal cancer survivors do not obtain recommended follow up care. • Patients will be randomized to CTAC or a control website that provides general information about cancer survivorship. • Patients must have a support person to be eligible for the study, however it is their choice to invite their support person to participate in the study with them. • Patients will complete paper surveys at baseline, month 3, and month 16. • The University of Michigan will host the CTAC and control websites, send website login information, and electronic gift cards to enrolled participants <p>Please contact <i>Alaina Newsome</i> (underberga@sjchs.org), GA NCORP CCDR Program Coordinator if you are interested in participating or for questions.</p>	
Wake Forest	WF24-09-26CD: Surgical Thromboprophylaxis Practices in Oncology Patients within the NCORP Network (STOP-VTE)	<ul style="list-style-type: none"> • Recruiting surgeons who perform abdominopelvic surgery • Expected start: Late Fall 2025

This newsletter was generated by:

TOPIC	PAGE
Pending CCDR Trials	1
Enrolling CCDR, New Treatment, and NCI High Priority Trials	2
Staff & Site Acknowledgements	3
Upcoming Meetings & Audits	4
Audit Prep Tips	5

CLINICAL RESEARCH NEWS

ALL OPEN AND ENROLLING CANCER CARE DELIVERY RESEARCH (CCDR) TRIALS¹

Research Base	Title	CTSU Activation Date
ECOG-ACRIN	EAQ221CD: Mobile Health for Adherence in Breast Cancer Patients (CONCURxP) <i>Deemed high priority by the Executive Committee.</i>	10/31/2023
	EAQ222CD: Cost Communication and Financial Navigation in Cancer Patients (COSTCOM) <i>Sites must receive approval prior to initiating any study start-up activities.</i>	2/29/2024
Wake Forest	WF-2301CD: Multi-site Community Oncology Planning for the CONNECT Intervention Targeting Lung Cancer Caregivers <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/2/2024
	WF-2303CD: Understanding and Enhancing Health-Related Social Needs (HRSN) Screening Among Community Oncology Practice <i>Closed to accepting new sites. Contact Jess Sheedy (jsheedy@wakehealth.edu) to get on the waitlist.</i>	7/23/2024

RECENTLY ACTIVATED TREATMENT TRIALS; POSTED MAY 2025²

Children's Oncology Group (COG)	AALL2131: An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia	5/23/2025
---------------------------------	---	-----------


NCI DESIGNATED HIGH PRIORITY TRIALS

Alliance	A212102: Blinded Reference Set For Multicancer Early Detection Blood Tests	08/01/2022
----------	--	------------

1. Contact Alaina Newsome (underberga@sjchs.org), GA NCORP CCDR Program Coordinator for questions.


2. Please refer to previous newsletters to learn about other trials.

CLINICAL RESEARCH NEWS



AUGUST 2024-MAY 2025 CCCR ENROLLMENT KUDOS:

- Pearlman Cancer Center: Dr. Savita Bidyasar, Dr. Samuel Ofori, Julie Thomas, RN, and Judie Wilder, RN
- Lewis Cancer and Research Pavilion at Saint Joseph's/Candler (LCRP): Ellie Dean, Dr. Ronald Goldberg, Dr. Lester Robertson, and Stephanie Reyes, RN



CLINICAL RESEARCH NEWS

UPCOMING RESEARCH BASE MEETINGS

Research Base	Date	Location
ECOG	October 22-24, 2025	Philadelphia, PA
NRG	July 24-26, 2025	Washington, DC
SWOG	September 17-20, 2025	Chicago, IL
URCC	September 25-28, 2025	Niagara Falls, NY
Wake Forest	October 6-8, 2025	Asheville, NC

Please contact Shantoria Brown (sbrown@georgiacore.org) to discuss travel funds.

UPCOMING ROUTINE AUDITS

Research Base	Date	Location
ECOG	TBD FOR 2026	TBD
NRG	TBD	TBD
SWOG	TBD for 2027	TBD
URCC	TBD for 2027	TBD
Wake Forest	TBD for 2027	TBD

UPCOMING GENERAL MEETINGS

Organizer	Meeting Title	Date	Location
Northside Hospital	GA NCORP 12 th Annual Investigators Meeting*	August 21, 2025 5:30-8:00 pm	The Hotel at Avalon 9000 Avalon Blvd Alpharetta, GA 30009
Georgia Society of Clinical Oncology (GASCO)	GASCO 2025 Annual Meeting & Best of ASCO	August 22-23, 2025	The Hotel at Avalon 9000 Avalon Blvd Alpharetta, GA 30009

*This event will be a Dinner & Reception hosted by Northside Hospital. This special evening will provide an opportunity to connect with your peers, share insights, and explore future collaborations in a relaxed and elegant setting. In-person and virtual options are available. Please go to the following link to register: <https://georgiacore.knack.com/untitled-app-5#home/> or contact Michelle Young (michelle.young@northside.com) for questions or concerns.

CLINICAL RESEARCH NEWS

AUDIT PREPARATION TIPS

- Conduct ongoing peer-to-peer monitoring
- Close open queries and share trends with team members
- Review internally issued and research base specific Corrective and Preventative Action (CAPA) plans for successful implementation and standardization
- Reconcile pharmacy records/DARFs against subject source and EDC
- Verify PI (or delegated designee) has signed eligibility checklists and AE logs
- Ensure there is an Informed Consent document and discussion for each ICF
- Confirm regulatory binder is current with initial and continuing submissions and approvals, delegation of duty log, training, sponsor memos, note-to-files, etc.
- Do not file internal communication that may be used a “paper trail”.

TEST OF YOUR KNOWLEDGE!

The first person to answer correctly will receive Georgia NCORP swag and a shout-out in the next issue! Send your responses to srichburg@georgiacore.org.

#1: What type of cancer is staged using the TNM system?

Choices: Leukemia or Osteosarcoma

#2: If there is more than one strength/dose of a drug for the same protocol, can you use the same Drug Accountability Record Form (DARF)?

Choices: Yes or No

#3: Radiation given before chemo, to shrink a tumor, is called what type of treatment?

Choices: Adjuvant or Neoadjuvant

Responses to March's TEST OF YOUR KNOWLEDGE! Congrats again to Terri Brannon, RN, CCRC!

#1: What type of treatment is given to help keep the cancer from coming back?

Choices: Induction, Reinduction, or Maintenance

Answer: Maintenance

#2: Which treatment is most likely to disrupt the immune system?

Choices: Pembrolizumab or Carboplatin

Answer: Pembro

#3: Which lab panel assesses anemia?

Choices: Complete Blood Count (CBC) or Comprehensive Metabolic Panel (CMP)

Answer: CBC